

17 September 2026

ASX Announcement

PolyNovo Appoints Dean Phizacklea and Andrew Price as Non-Executive Directors

PolyNovo Limited (**ASX: PNV**) is pleased to announce the appointment of Dean Phizacklea and Andrew Price as Non-Executive Directors of the Company, effective 18 September 2026. The appointments form part of the Board's ongoing renewal program and reflect a review of the skills and experience required to support PolyNovo's next phase of growth.

Chair Leon Hoare said:

"We are delighted to welcome Dean and Andrew to the PolyNovo Board. Dean brings extensive experience in global commercial leadership, market access and growth strategy, while Andrew contributes deep expertise in global supply chain, manufacturing, quality and operational excellence developed over many years in the medical technology sector. Together, they bring complementary skills and perspectives that will further strengthen the Board as PolyNovo continues to scale globally and pursue its long-term growth opportunities."

Dean Phizacklea

Dean is currently Senior Vice President, Global Strategic Marketing at Cochlear and brings more than 30 years' experience in the global medical technology sector, spanning commercial leadership, market access, clinical affairs and growth strategy. He has previously held senior executive roles at Cochlear and Abbott, where he was responsible for driving international growth, expanding market access and leading high-performing commercial organisations across developed and emerging markets.

Andrew Price

Andrew brings more than 25 years of experience in global supply chain, manufacturing, quality and regulatory leadership within the medical technology industry. He spent over two decades with ResMed (NYSE: RMD, ASX: RMD), including in senior executive roles with responsibility for large-scale manufacturing operations and global supply networks. His experience in scaling manufacturing capability, quality systems and operational performance will support PolyNovo's continued global expansion. Andrew currently serves as a Non-Executive Director of SomnoMed Limited (ASX: SOM), where he is a member of the Audit and Risk Committee.

The Board has determined that Dean and Andrew are independent Non-Executive Directors. They will stand for election by shareholders at the Company's 2026 Annual General Meeting.


Board Renewal and Director Retirements

The appointments follow the decisions of both Christine Emmanuel-Donnelly and Dr Robyn Elliott to retire from the Board and to not seek re-election at the 2026 Annual General Meeting.

Mr Hoare thanked both directors for their highly significant contribution to PolyNovo over many years.



PolyNovo Limited (ASX: PNV) ABN 96 083 866 862
2/320 Lorimer Street, Port Melbourne, Victoria 3207 Australia
+61 3 8681 4050 investor@polynovo.com
investors.polynovo.com



"Christine and Robyn have each played a vitally important role in PolyNovo's development and success, providing valued leadership, insight and stewardship during a period of significant growth and transformation for the Company. On behalf of the Board, management, and shareholders, I thank them for their dedication, contribution, commitment and service and wish them every success for the future."

Dr Elliott has served on the Board for seven years, providing strategic guidance across operations and quality functions while supporting the Company's growth and operational maturity. She also stepped into the role of Acting Interim Chief Executive Officer from March to December 2025, providing stability and leadership during a critical transition period for the Company.

Ms Emmanuel-Donnelly has served on the Board for more than six years. As Chair of the Remuneration Committee, she led significant remuneration reform and has also provided trusted counsel to the Board on intellectual property, commercialisation and governance matters.

Both leave the Board with PolyNovo's sincere thanks and appreciation for their very significant contribution to the Company.

This announcement has been authorised by the PolyNovo Board of Directors.

Further information:

Amy Demediuk, General Counsel & Company Secretary

Mobile: + 61 419 858 691

Email: amy.d@polynovo.com

Media contact:

media@polynovo.com

About PolyNovo®

PolyNovo (ASX: PNV) is a leading medical technology company transforming the management of complex wounds. Headquartered in Melbourne, Australia, it has international operations in the United States, United Kingdom, India, Hong Kong and Singapore and several other markets supported by distributor partners.

The proprietary NovoSorb® polymer is addressing significant unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the Company is leveraging the technology platform to develop new products and markets.

Achievements to date, including continued revenue growth, profitability, numerous clearances and registrations, as well as market leadership in several geographies, provide a strong foundation for continued growth.

For more information see polynovo.com

[View this announcement on PolyNovo's investor hub](#)